PolyPid Ltd
NASDAQ:PYPD
PolyPid Ltd
Research & Development
PolyPid Ltd
Research & Development Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Research & Development | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
PolyPid Ltd
NASDAQ:PYPD
|
Research & Development
-$23.8m
|
CAGR 3-Years
5%
|
CAGR 5-Years
-7%
|
CAGR 10-Years
N/A
|
|
|
Teva Pharmaceutical Industries Ltd
TASE:TEVA
|
Research & Development
-$1B
|
CAGR 3-Years
-7%
|
CAGR 5-Years
0%
|
CAGR 10-Years
4%
|
|
|
Sol Gel Technologies Ltd
NASDAQ:SLGL
|
Research & Development
-$24.4m
|
CAGR 3-Years
-22%
|
CAGR 5-Years
4%
|
CAGR 10-Years
N/A
|
|
|
Mediwound Ltd
NASDAQ:MDWD
|
Research & Development
-$12.8m
|
CAGR 3-Years
-9%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
-9%
|
|
|
T
|
Tikun Olam Cannbit Pharmaceuticals Ltd
TASE:TKUN
|
Research & Development
-₪145k
|
CAGR 3-Years
71%
|
CAGR 5-Years
35%
|
CAGR 10-Years
N/A
|
|
|
R
|
Rekah Pharmaceutical Industry Ltd
TASE:REKA
|
Research & Development
-₪4.4m
|
CAGR 3-Years
-13%
|
CAGR 5-Years
-22%
|
CAGR 10-Years
-5%
|
|
PolyPid Ltd
Glance View
PolyPid Ltd. is a clinical stage biopharmaceutical company focusing on the development, manufacture, and commercialization of administered therapies to improve surgical outcomes. The firm focuses on the development, production and commercialization of new, locally administered therapies to improve surgical results. The main product is PLEX technology, which is located in the place of surgery and ensures controlled and continuous delivery of medicines.
See Also
What is PolyPid Ltd's Research & Development?
Research & Development
-23.8m
USD
Based on the financial report for Dec 31, 2025, PolyPid Ltd's Research & Development amounts to -23.8m USD.
What is PolyPid Ltd's Research & Development growth rate?
Research & Development CAGR 5Y
-7%
Over the last year, the Research & Development growth was -4%. The average annual Research & Development growth rates for PolyPid Ltd have been 5% over the past three years , -7% over the past five years .
